U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula Fe.O
Molecular Weight 71.844
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FERROUS OXIDE

SMILES

[O--].[Fe++]

InChI

InChIKey=VBMVTYDPPZVILR-UHFFFAOYSA-N
InChI=1S/Fe.O/q+2;-2

HIDE SMILES / InChI
Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Fe
Molecular Weight 55.845
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3541174 | https://books.google.ru/books?id=7mxyBgAAQBAJ&pg=PA13&lpg=PA13&dq=%22ferrous+iodide%22+anemia&source=bl&ots=ZGyFhUiJZ4&sig=IZOhRVaGmlwX7GcqgoE6rnCsCa4&hl=ru&sa=X&ved=0ahUKEwjYu7PCyYHUAhWiQpoKHR6cCfcQ6AEIUjAJ#v=onepage&q=%22ferrous%20iodide%22&f=false

There is no information about biological and pharmacological application of Iron(II) fluoride (also known as ferrous fluoride). It is known, that this substance is used to catalyze some organic reactions.

Originator

Approval Year

1921
1468
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Not Provided
511
Unknown

Approved Use

Unknown
Palliative
Not Provided
511
Unknown

Approved Use

Unknown
Primary
Approved
8583
Ferro Sanol Duodenal

Approved Use

Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
Curative
Approved
8583
RADIOGARDASE

Approved Use

Insoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination.

Launch Date

2003
PubMed

PubMed

TitleDatePubMed
Clinical appraisal of drugs with special reference to a new chelate hematinic.
1957 Jul 11
Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis.
2007
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia.
2010 Dec
Tolerability of different oral iron supplements: a systematic review.
2013 Apr
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.
2014
Patents

Patents

CN105565963
37
US20020127665
37
US2009028810
37
US20150202224
37
US2877253
37
US3091626
37
US5534268
37
US6407138
37
US8080520
37
US8802114
37

Sample Use Guides

In Vivo Use Guide
Adults should usually take one capsule a day. In cases of pronounced iron deficiency, adults can be given a dosage 2 to 3 times higher at the beginning of therapy. A daily dose of more than 5 mg Fe2+/kg body weight should in-well founded exceptional cases not be exceeded.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:30:20 GMT 2025
Edited
by admin
on Mon Mar 31 18:30:20 GMT 2025
Record UNII
G7036X8B5H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FERROUS OXIDE
HSDB   II   MI   VANDF  
Common Name English
CI 77489
INCI  
INCI  
Preferred Name English
FERROUS OXIDE [II]
Common Name English
IRON MONOXIDE
Common Name English
FERROUS OXIDE [HSDB]
Common Name English
IRON(II) OXIDE
Common Name English
FERROUS OXIDE [VANDF]
Common Name English
IRON OXIDE (FEO)
Common Name English
FERROUS OXIDE [MI]
Common Name English
Iron oxides [WHO-DD]
Common Name English
C.I. 77489
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID1041976
Created by admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
PRIMARY
MERCK INDEX
m5349
Created by admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
PRIMARY Merck Index
FDA UNII
G7036X8B5H
Created by admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
PRIMARY
MESH
C034236
Created by admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
PRIMARY
RXCUI
1363047
Created by admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
PRIMARY RxNorm
PUBCHEM
449809
Created by admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
PRIMARY
WIKIPEDIA
IRON(II) OXIDE
Created by admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
PRIMARY
ECHA (EC/EINECS)
215-721-8
Created by admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
PRIMARY
CHEBI
50820
Created by admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
PRIMARY
DAILYMED
G7036X8B5H
Created by admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
PRIMARY
CAS
1345-25-1
Created by admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
PRIMARY
HSDB
464
Created by admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
PRIMARY
Related Record Type Details
Structure of FERROUS CATION
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of FERROUS CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966